115 related articles for article (PubMed ID: 38438140)
21. Effects of bisphosphonate administration on the bone mass in immune thrombocytopenic purpura patients under treatment with steroids.
Nomura S; Kurata Y; Tomiyama Y; Takubo T; Hasegawa M; Saigo K; Nishikawa M; Higasa S; Maeda Y; Hayashi K
Clin Appl Thromb Hemost; 2010 Dec; 16(6):622-7. PubMed ID: 19959489
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of anti-D for treatment of adults with immune thrombocytopenia.
Naithani R; Kumar R; Mahapatra M; Tyagi S; Saxena R
Platelets; 2009 Nov; 20(7):525-7. PubMed ID: 19852693
[TBL] [Abstract][Full Text] [Related]
23. Disease management of patients with immune thrombocytopenia-results of a representative retrospective survey in Germany.
Kubasch AS; Kisro J; Heßling J; Schulz H; Hurtz HJ; Klausmann M; Ehrnsperger A; Willy C; Platzbecker U
Ann Hematol; 2020 Sep; 99(9):2085-2093. PubMed ID: 32710167
[TBL] [Abstract][Full Text] [Related]
24. Initial Management of Childhood Acute Immune Thrombocytopenia: Single-Center Experience of 32 Years.
Yildiz I; Ozdemir N; Celkan T; Soylu S; Karaman S; Canbolat A; Dogru O; Erginoz E; Apak H
Pediatr Hematol Oncol; 2015; 32(6):406-14. PubMed ID: 26154620
[TBL] [Abstract][Full Text] [Related]
25. Corticosteroid Risk Function of Severe Infection in Primary Immune Thrombocytopenia Adults. A Nationwide Nested Case-Control Study.
Moulis G; Palmaro A; Sailler L; Lapeyre-Mestre M
PLoS One; 2015; 10(11):e0142217. PubMed ID: 26559054
[TBL] [Abstract][Full Text] [Related]
26. Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study.
Lafaurie M; Maquet J; Baricault B; Ekstrand C; Christiansen CF; Linder M; Bahmanyar S; Nørgaard M; Sailler L; Lapeyre-Mestre M; Sommet A; Moulis G
Br J Haematol; 2021 Nov; 195(3):456-465. PubMed ID: 34386974
[TBL] [Abstract][Full Text] [Related]
27. Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial.
Pell J; Greenwood R; Ingram J; Wale K; Thomas I; Kandiyali R; Mumford A; Dick A; Bagot C; Cooper N; Hill Q; Bradbury CA
BMJ Open; 2018 Oct; 8(10):e024427. PubMed ID: 30341143
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia.
Togasaki E; Shimizu N; Nagao Y; Kawajiri-Manako C; Shimizu R; Oshima-Hasegawa N; Muto T; Tsukamoto S; Mitsukawa S; Takeda Y; Mimura N; Ohwada C; Takeuchi M; Sakaida E; Iseki T; Yoshitomi H; Ohtsuka M; Miyazaki M; Nakaseko C
Ann Hematol; 2018 Apr; 97(4):655-662. PubMed ID: 29332223
[TBL] [Abstract][Full Text] [Related]
29. Chronic idiopathic thrombocytopenic purpura in adult Chinese patients: a retrospective single-centered analysis of 1791 cases.
Li HQ; Zhang L; Zhao H; Ji LX; Yang RC
Chin Med J (Engl); 2005 Jan; 118(1):34-7. PubMed ID: 15642223
[TBL] [Abstract][Full Text] [Related]
30. Investigation of TNF-alpha, TGF-beta 1, IL-10, IL-6, IFN-gamma, MBL, GPIA, and IL1A gene polymorphisms in patients with idiopathic thrombocytopenic purpura.
Pehlivan M; Okan V; Sever T; Balci SO; Yilmaz M; Babacan T; Pehlıvan S
Platelets; 2011; 22(8):588-95. PubMed ID: 21591983
[TBL] [Abstract][Full Text] [Related]
31. Incidence, clinical characteristics, and associated diseases in patients with immune thrombocytopenia: A nationwide population-based study in Taiwan.
Wu SR; Kuo HC; Huang WC; Huang YF; Chiou YH; Chang YH; Nong BR
Thromb Res; 2018 Apr; 164():90-95. PubMed ID: 29522912
[TBL] [Abstract][Full Text] [Related]
32. Risk of cataract among idiopathic thrombocytopenic purpura patients in the UK general practice research database.
Feudjo-Tepie MA; Hall SA; Logie J; Robinson NJ
Pharmacoepidemiol Drug Saf; 2009 May; 18(5):380-5. PubMed ID: 19241439
[TBL] [Abstract][Full Text] [Related]
33. Idiopathic thrombocytopenic purpura is strongly associated with higher prevalence of aortic valve disease.
Haseefa F; Movahed MR; Hashemzadeh M; Hashemzadeh M
Ann Hematol; 2020 Sep; 99(9):2081-2084. PubMed ID: 32691113
[TBL] [Abstract][Full Text] [Related]
34. Megakaryocyte morphology and its impact in predicting response to steroid in immune thrombocytopenia.
Tripathi AK; Mishra S; Kumar A; Yadav D; Shukla A; Yadav Y
Platelets; 2014; 25(7):526-31. PubMed ID: 24246033
[TBL] [Abstract][Full Text] [Related]
35. Incidence and prevalence of immune thrombocytopenia under the copayment waiver policy for pediatric patients in Korea: Data from the National Health Claims Database.
Park SH; Kwak SG; Kim JY
Lupus; 2021 Apr; 30(4):655-660. PubMed ID: 33593162
[TBL] [Abstract][Full Text] [Related]
36. Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012.
Michel M; Suzan F; Adoue D; Bordessoule D; Marolleau JP; Viallard JF; Godeau B
Br J Haematol; 2015 Jul; 170(2):218-22. PubMed ID: 25824587
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany.
Meyer O; Richter H; Lebioda A; Schill M
Hematology; 2021 Dec; 26(1):697-708. PubMed ID: 34547980
[TBL] [Abstract][Full Text] [Related]
38. Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort.
Moulis G; Germain J; Comont T; Brun N; Dingremont C; Castel B; Arista S; Sailler L; Lapeyre-Mestre M; Beyne-Rauzy O; Godeau B; Adoue D;
Am J Hematol; 2017 Jun; 92(6):493-500. PubMed ID: 28240787
[TBL] [Abstract][Full Text] [Related]
39. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
40. Immune thrombocytopenic purpura might be an early hematologic manifestation of undiagnosed human immunodeficiency virus infection.
Lai SW; Lin HF; Lin CL; Liao KF
Intern Emerg Med; 2017 Mar; 12(2):157-162. PubMed ID: 27562379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
